Proton MRS in Mild Cognitive Impairment

Overview

Journal J Magn Reson Imaging

Date 2013 Mar 26

PMID 23526756

Citations 31

Authors

Kejal Kantarci

Affiliations

Soon will be listed here.

Abstract

Mild cognitive impairment (MCI) is a clinical syndrome operationalized for early diagnosis and treatment of Alzheimer's disease (AD). Many individuals with MCI are at the prodromal stage of AD or other dementia. Various quantitative magnetic resonance imaging (MRI) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures for early diagnosis and disease progression in MCI. The pathology underlying MCI is heterogeneous, dominated by AD, cerebrovascular disease, Lewy body disease, or a mixture of these pathologies in autopsy cohorts. Proton magnetic resonance spectroscopy ((1)H MRS) metabolite markers may help identify and track etiologies that typically underlie MCI in the elderly. The role of proton MRS will be critical for pathophysiological processes for which a reliable biomarker does not exist such as neuronal dysfunction, glial and microglial activation in MCI.

Citing Articles

Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers.

Dang C, Wang Y, Li Q, Lu Y Psychoradiology. 2024; 3:kkad009.

PMID: 38666112 PMC: 11003434. DOI: 10.1093/psyrad/kkad009.

Preliminary study on early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice using multimodal magnetic resonance imaging.

Xu M, Liu J, Liu Q, Gong Y, Li Y, Zhang J Front Aging Neurosci. 2024; 16:1326394.

PMID: 38419647 PMC: 10899441. DOI: 10.3389/fnagi.2024.1326394.

N-acetyl-aspartate and Myo-inositol as Markers of White Matter Microstructural Organization in Mild Cognitive Impairment: Evidence from a DTI-H-MRS Pilot Study.

Valatkeviciene K, Levin O, Sarkinaite M, Vints W, Kunickaite R, Danyle G Diagnostics (Basel). 2023; 13(4).

PMID: 36832141 PMC: 9955118. DOI: 10.3390/diagnostics13040654.

H-MRS neurometabolites and associations with neurite microstructures and cognitive functions in amnestic mild cognitive impairment.

Gozdas E, Hinkley L, Fingerhut H, Dacorro L, Gu M, Sacchet M Neuroimage Clin. 2022; 36:103159.

PMID: 36063758 PMC: 9450331. DOI: 10.1016/j.nicl.2022.103159.

Hyperglycemia and hyperinsulinemia effects on anterior cingulate cortex myoinositol-relation to brain network functional connectivity in healthy adults.

Bolo N, Jacobson A, Musen G, Simonson D J Neurophysiol. 2022; 127(5):1426-1437.

PMID: 35417272 PMC: 9109787. DOI: 10.1152/jn.00408.2021.

References

Mariani E, Monastero R, Ercolani S, Mangialasche F, Caputo M, Feliziani F . Vascular risk factors in mild cognitive impairment subtypes. Findings from the ReGAl project. Dement Geriatr Cogn Disord. 2007; 24(6):448-56. DOI: 10.1159/000110653. View

Chantal S, Braun C, Bouchard R, Labelle M, Boulanger Y . Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res. 2004; 1003(1-2):26-35. DOI: 10.1016/j.brainres.2003.11.074. View

Thal L, Kantarci K, Reiman E, Klunk W, Weiner M, Zetterberg H . The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006; 20(1):6-15. PMC: 1820855. DOI: 10.1097/01.wad.0000191420.61260.a8. View

Molano J, Boeve B, Ferman T, Smith G, Parisi J, Dickson D . Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. 2009; 133(Pt 2):540-56. PMC: 2822633. DOI: 10.1093/brain/awp280. View

Tiraboschi P, Hansen L, Alford M, Merdes A, Masliah E, Thal L . Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002; 59(10):946-51. DOI: 10.1001/archpsyc.59.10.946. View

Chen S, Wang P, Ten G, Zhan W, Li M, Zang F . Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord. 2010; 28(6):558-66. PMC: 2837893. DOI: 10.1159/000261646. View

Shonk T, Moats R, Gifford P, Michaelis T, Mandigo J, Izumi J . Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology. 1995; 195(1):65-72. DOI: 10.1148/radiology.195.1.7892497. View

Wegiel J, Tarnawski M, Bobinski M, Reisberg B, de Leon M, Miller D . Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol. 1997; 56(4):414-20. DOI: 10.1097/00005072-199704000-00010. View

Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J . Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999; 20(9):1619-27. PMC: 7056180. View

10.

Mohanakrishnan P, Fowler A, Vonsattel J, Jolles P, Husain M, Liem P . Regional metabolic alterations in Alzheimer's disease: an in vitro 1H NMR study of the hippocampus and cerebellum. J Gerontol A Biol Sci Med Sci. 1997; 52(2):B111-7. DOI: 10.1093/gerona/52a.2.b111. View

11.

Shonk T, Ross B . Role of increased cerebral myo-inositol in the dementia of Down syndrome. Magn Reson Med. 1995; 33(6):858-61. DOI: 10.1002/mrm.1910330619. View

12.

Bennett D, Schneider J, Bienias J, Evans D, Wilson R . Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005; 64(5):834-41. DOI: 10.1212/01.WNL.0000152982.47274.9E. View

13.

Krishnan K, Charles H, Doraiswamy P, Mintzer J, Weisler R, Yu X . Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003; 160(11):2003-11. DOI: 10.1176/appi.ajp.160.11.2003. View

14.

Moats R, Ernst T, Shonk T, Ross B . Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med. 1994; 32(1):110-5. DOI: 10.1002/mrm.1910320115. View

15.

Kantarci K, Knopman D, Dickson D, Parisi J, Whitwell J, Weigand S . Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology. 2008; 248(1):210-20. PMC: 2735577. DOI: 10.1148/radiol.2481071590. View

16.

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

17.

Sperling R, Jack Jr C, Aisen P . Testing the right target and right drug at the right stage. Sci Transl Med. 2011; 3(111):111cm33. PMC: 3752906. DOI: 10.1126/scitranslmed.3002609. View

18.

Brand A, Richter-Landsberg C, Leibfritz D . Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993; 15(3-5):289-98. DOI: 10.1159/000111347. View

19.

Huang W, Alexander G, Chang L, Shetty H, Krasuski J, Rapoport S . Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology. 2001; 57(4):626-32. DOI: 10.1212/wnl.57.4.626. View

20.

Waldman A, Rai G, McConnell J, Chaudry M, Grant D . Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr. 2004; 35(2):137-42. DOI: 10.1016/s0167-4943(02)00014-6. View